Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Emepepimut-S |
Synonyms | |
Therapy Description |
Stimuvax (emepepimut-S) is a peptide vaccine comprised of synthetic peptide based on Muc-1 protein, which may enhance immune response to Muc-1 expressing tumor cells (PMID: 21689064. |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Emepepimut-S | Stimuvax|L-BLP25|BP1-7-KLH|tecemotide | Stimuvax (emepepimut-S) is a peptide vaccine comprised of synthetic peptide based on Muc-1 protein, which may enhance immune response to Muc-1 expressing tumor cells (PMID: 21689064. |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00828009 | Phase II | Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |